Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Vanilloid receptor desensitization as a strategy for improving glucose tolerance as well as reducing diabetic neuropathic pain

27 Jul 05

The vanilloid capsaicin has long been known to desensitize pain pathways leading to long-term analgesia. Recent data from Novo Nordisk A/S suggests that sensory afferents might also be implicated in the development of glucose intolerance.

So You Want to Contract Staff?

27 Jul 05

It is now the norm for clinical and medical departments to work with a mixture of headcount, freelance and contract employees as well as outsourcing whole projects and there is no indication that going into 2005 and beyond, that there will be any change in this trend.
i3 Pharma Resourcing

Renalase as a new target for the treatment of cardiovascular disease particularly amongst patient with end-stage renal disease

26 Jul 05

The antihypertensive market was valued at $31 billion in 2003. The kidney plays an important role in regulating blood pressure and the renal enzyme renin is a target for what is expected to be the next blockbuster class of anti-hypertensives. The report highlighted here identifies a further renal enzyme, renalase that may be another target for the treatment of hypertension.

Improved assay technology for the evaluation of airway therapeutic activity or toxicology

21 Jul 05

Assaying therapeutic agents requires the availability of apparatus to dose experimental animals as well as to measure biological effect. Available dosing systems for inhalation agents are suboptimal generally causing stress to the animal as well as exposing the operator to potentially harmful agents. Texas based researchers have developed an improved system for the delivery of agents to the airway

Viramidine (Valeant Pharmaceuticals), a ribavirin prodrug for the improved treatment of hepatitis C (HCV) infection

18 Jul 05

Hepatitis C virus (HCV) infection produces cirrhosis, end-stage liver disease and liver cancer and by 2010 38,000 deaths will result from infection. Anemia associated with ribavirin, a common treatment of infected patients represents a major problem. Valeant Pharmaceutical have developed a prodrug of ribavirin, viramidine which is activated within the liver resulting in reduced levels of ribavirin accumulating in red blood cells thus overcoming the problem of anemia.

Novel non-hydroxamic histone deactylase (HDAC) inhibitors in development from Miikana

14 Jul 05

The field of histone deacetylase inhibitors is moving into a new phase of development with candidates advancing nicely through clinical development. Milkana hasve recently developed a series of non-hydroxamic histone deactylase inhibitors which are likely to demonstrate an improved toxcity profile

The mGlu5 receptor: a target for antagonists with improved anxiolytic activity

13 Jul 05

Anxiety disorders affect 20% of the total population across the seven major markets. Recent data demonstrates the efficacy of MPEP, the prototypical mGlu5 receptor antagonist as a an anxiolytic. Efficacy was similar compared to that of diazepam but at anxiolytic doses produces less cognitive decline

DailyUpdates: Breaking Journal Articles & Press Releases for the Drug Development Sector

08 Jul 05

DailyUpdates was developed in 2002 by the drug development consultants, LeadDiscovery. Developed for the R&D community, 1,000's of individuals plus many of the top 20 pharmaceutical companies now use this simple yet effective tool to track key events in the drug discovery sector.

Histone deacetylase inhibitors

06 Jul 05

The field of histone deacetylase inhibitors is moving into a new phase of development. The exponential growth in the level of research activity surrounding the histone deacetylases (HDACs) witnessed over the past decade has now started to produce success in the clinic, particularly in the field of oncology. Over the next few years experts believe that as first generation HDAC inhibitors produce clinical benefits and second generation inhibitors are rationally designed with improved specificity

Aurora Kinase inhibitors

01 Jul 05

Cell cycle inhibitors represent a key approach to the treatment of cancer. Therapeutic agents have traditionally targeted early stages of the cell cycle (ie the G1/S phase checkpoint or the S phase) or mitotic spindle formation as exemplified by the alkaloids. Recently a new approach to cell cycle regulation has emerged with the identification of the Aurora kinase family. This report evaluates this exciting area of drug discovery

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.